Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

NCT01988493 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Tepotinib 300 mg
DRUG: Tepotinib 500 mg
DRUG: Tepotinib 1000 mg
DRUG: Tepotinib
DRUG: Sorafenib

Sponsor

Merck KGaA, Darmstadt, Germany